OR WAIT null SECS
ILD is a very broad category of chronic lung conditions with considerable nuance. Glassberg joins to discuss the roles of biomarkers, biopsies and drugs, as well as multidisciplinary clinics and stem cell therapy.
0:16 The clinical history of ILD
2:39 Introducing Dr. Marilyn Glassberg
4:50 Identifying ILD
9:33 Innovations in diagnostics and care
13:40 Multidisciplinary clinics for ILD
16:52 Anti-fibrotic strategies
22:02 Stem cell therapy
28:10 Learning from long COVID-19
30:49 Outro
The umbrella of interstitial lung disease (ILD) covers approximately 200 chronic respiratory conditions. Most of them rare in form; too many of them debilitating in effect and too frequently unrecognized by clinicians.
Despite these hurdles in identification and timely treatment, the field of ILD—and its most recognized condition, idiopathic pulmonary fibrosis (IPF)—have been subject to great advances in therapeutic options and capability. And as one of the most prominent ILD researchers explained, there may be even greater developments in the near future.
This month’s episode of Lungcast features an interview with Marilyn Glassberg, MD, Chair of Pulmonary Medicine, Critical Care and Sleep Medicine at the University of Arizona College of Medicine. Glassberg, a renowned expert of rare respiratory diseases, joined American Lung Association (ALA) Chief Medical Officer Al Rizzo, MD, for a discussion on the multifaceted developments in ILD screening, diagnostics, referral and care.
Lungcast is a monthly respiratory health podcast series from the ALA, produced by HCPLive.
Subscribe or listen to Lungcast on your favorite platforms:
